Psychiatry and Clinical Psychopharmacology

Psikofarmakoloji Comparison of short-acting and osmotic releasing form of methylphenidate in children diagnosed with attention deficit and hyperactivity disorder

Psychiatry and Clinical Psychopharmacology 2013; 23: Supplement S93-S94
Keywords : ADHD, methylphenidate
Read: 364 Published: 20 March 2021

Objective: Attention deficit-hyperactivity disorder effects children's home and school life quality also academic performance and relationships with their friends and teachers if treated inappropriately. In treatment of ADHD, that is combined pharmacological and behavioral treatment; and most common used pharmacological agent is methylphenidate. In this study we aimed to compare Short-acting and osmotic releasing form of methylphenidate's differences between periods of usage, before and after Family and Teacher Scores, clinical assessment points and prognosis.

Method: Participants were 81 children with diagnosed ADHD who participated in a longitudinal study from age 7 to 17 (mean:10,6).In the beginning of treatment ADHD Parent Rating Scale and Teacher Rating Scale was completed by their parents and teachers and repeated after 12 weeks. Clinical assessment done with Clinical Global Impression (CGI) at the week of 6th and 12th of treatment.

Results: In the beginning of treatment there were no differences between two groups in age, gender, comorbidity and start-up CGI, Family, Teacher scores. After clinical assessment OROS is used 18-36mg (mean 27,5) SAM is used 15-30 mg (24,3). Our findings demonstrated in both groups CGI scores improved significantly in the week of 6th and 12th. Compared to OROS, SAM group CGI improved better with mean differences (p:0,038). On the other hand there were no differences between improvement of Family scores, but Teacher scores slightly better in SAM group and our study found no correlation between Family, Teacher scores and CGI scores.

Discussion: In our study demonstrates a slight preference towards OROS or SAM on certain core symptoms, we found SAM more effective on clinical assessment also showed no significant differences between SAM and OROS in family and teacher scores. Education level of the family showed correlation with improvement of CGI, Teacher and Family scores. OROS can cost up to 20 times more than SAM without evidence of greater compliance and for children with ADHD symptoms are affecting their school performance, family life quality, SAM will be found to be effective by teachers.
 

EISSN 2475-0581